Dr. Scott Vafai is the senior vice president of clinical development at Verve Therapeutics. He has more than 10 years of experience in drug discovery and development, including extensive expertise in clinical and regulatory strategy, translational medicine, and genomic medicine. Scott joined Verve in 2020 and has played a pivotal role in advancing the PCSK9 program since that time. Prior to joining Verve, Scott served as senior director of translational medicine and clinical pharmacology at Sanofi with a focus on gene therapy clinical development. He previously served as director of the mitochondrial therapeutics accelerator leading an industry-funded drug discovery group at the Broad Institute. Scott is co-founder of Metavention, a clinical stage company developing hepatic denervation for the treatment of type 2 diabetes.

Scott holds an A.B. in molecular biology from Princeton University and an M.D. from the Harvard-MIT Health Sciences and Technology Program. He completed his residency in internal medicine at Brigham and Women’s Hospital and fellowship in endocrinology at Massachusetts General Hospital. His post-doctoral training was focused on developing novel mitochondrial therapeutics with Dr. Vamsi Mootha at Massachusetts General Hospital and the Broad Institute.